SavedAdd your journal

Journals / Turkish Journal of Cancer / 2001 / Cilt: 31 - Sayı: 2

Resection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer

Ahmet ÖZET
Ali Aydın YAVZU
MEHMET MURAT BEYZADEOĞLU
Yaşar ÖZGÖK
Bekir ÖZTÜRK
Fikret ARPACI
Şeref KÖMÜRCÜ
Levent YAMANEL
Teoman DOĞRU
Pages
57–62
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our data presented herein imply that surgical removal of all post-chemotherapy residual masses is required before suggesting routine salvage chemotherapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Retroperitoneal lymph node dissection followed by chemotherapy for the treatment of nonseminomatous testis cancer is reserved for partial remissions.
📊
Key Findings & Data:One hundred and sixty seven patients with nonseminomatous testis cancer were admitted to Gülhane Military Medical Academy between the years of 1992-1999.
💡
Conclusion & Impact:Our data presented herein imply that surgical removal of all post-chemotherapy residual masses is required before suggesting routine salvage chemotherapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Lenf düğümü çıkartılması · Retroperitoneal neoplazmlar · Testis neoplazmları

Abstract

Retroperitoneal lymph node dissection followed by chemotherapy for the treatment of nonseminomatous testis cancer is reserved for partial remissions. One hundred and sixty seven patients with nonseminomatous testis cancer were admitted to Gülhane Military Medical Academy between the years of 1992-1999. Retroperitoneal residual masses determined radiologically were resected in 12 patients (9 teratocarcinoma, 3 embryonal carcinoma) with stage-B after cisplatin-based therapy (PVB in 8 and PEB in 4 patients). Alpha-fetoprotein (AFP) and beta subunit of human chorionic gonadotropin (p-HCG) levels in all patients were normal before resection. The pathologic evaluation of removed retroperitoneal masses showed residual malignancy in 6 patients, mature teratoma in 5 patients and necrosis in 1 patient. Patients with malignant residual tumour (n=6) received chemotherapy, and the others (n=6) were followed by surveillance only. Our data presented herein imply that surgical removal of all post-chemotherapy residual masses is required before suggesting routine salvage chemotherapy.

Özet

Resection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer

🔖

Cite This Article

ÖZET, A., YAVZU, A. A., BEYZADEOĞLU, M. M., ÖZGÖK, Y., ÖZTÜRK, B., ARPACI, F., KÖMÜRCÜ, Ş., YAMANEL, L., DOĞRU, T. (2001). Resection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer. Turkish Journal of Cancer, Cilt: 31 - Sayı: 2, 57–62. https://ajindex.com/articles/368390

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Einhorn LH. Treatment of testicular cancer: a new and improved model (editorial). J Clin Oncol 1990;8:1777-81
  2. Fox EP, Loehrer PJ. Chemotherapy for advanced testicular cancer. Hematol Oncol Clin North Am 1991;5:1173-87
  3. Tiffany P, Morse MJ, Bosl G, et al. Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. Cancer 1986;57:978-85
  4. Donohue J, Rowland R. The role of surgery in advanced testicular cancer. Cancer 1984;54:2716-21
  5. Loehrer P, Hui S, Clark S, et al. Teratoma following cisplatin based combination chemotherapy for nonseminomatous germ cell tumor. J Urol 1986;135:1183-9
  6. Geller N, Bosl G, Chan E. Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors. Cancer 1989;63:440- 5
  7. Donohue J, Fox EP, Williams S, et al. Persistent cancer in postchemotherapy retroperitoneal lymph node dissection: outcome analysis. World J Urol 1994;12:190-5
  8. Donohue J, Einhorn LH, Williams S. Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent. J Urol 1980;123:876-81
  9. Einhorn LH, Williams S, Troner M, et al. The role of maintenance therapy in disseminated germ cell cancer. N Engl J Med 1981;305:727-31
  10. Williams S, Birch R, Einhorn LH, et al. Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastin or etoposide. N Engl J Med 1987;31:1435-40
  11. Ondrus D, Hornak M, Matoska J, et al. Chemotherapy of testicular cancer: 10-year experience. Neoplasma 1993;40:247-53
  12. Qvist HL, Fossa SD, Ous S. Post-chemotherapy tumor residuals in patients with advanced nonseminomatous testicular cancer. Is it necessary to resect all residual masses? J Urol 1991;145:300-2, discussion 302-3
  13. Waples MJ, Messing EM. Redo retroperitoneal lymphadenectomy for germ cell tumor. Urology 1993;42:31-4
  14. Fossa SD, Aass N, Kaalhus O. Testicular cancer in young Norwegians. Surg Oncol 1988;39:43-63
  15. Fossa SD, Aass N, Ous S, et al. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol 1989;142:1239-42
  16. Stomper PC, Jochelson MS, Garnick MB, et al. Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: correlation of CT and histology. AJR 1985;145:743-6.